← All trials
NCT04964518
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 30, 2021
- Primary completion
- Jul 30, 2022
- Completion date
- Oct 30, 2023
- First posted
- Jul 16, 2021
- Last posted
- Jul 16, 2021
- Enrollment
- 72
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Ascentage Pharma Group Inc.Lead sponsor
- Ascentage Pharma Group Inc.Overall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.